Semantic prioritization of novel causative genomic variants by Boudellioua, Imane et al.
 
 
Semantic prioritization of novel causative genomic
variants
Boudellioua, Imane; Mahamad Razali, Rozaimi B; Kulmanov, Maxat; Hashish, Yasmeen;
Bajic, Vladimir B; Goncalves-Serra, Eva; Schoenmakers, Nadia; Gkoutos, Georgios;
Schofield, Paul N; Hoehndorf, Robert
DOI:
10.1371/journal.pcbi.1005500
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Boudellioua, I, Mahamad Razali, RB, Kulmanov, M, Hashish, Y, Bajic, VB, Goncalves-Serra, E, Schoenmakers,
N, Gkoutos, GV, Schofield, PN & Hoehndorf, R 2017, 'Semantic prioritization of novel causative genomic
variants', PLoS Computational Biology, vol. 13, no. 4, e1005500. https://doi.org/10.1371/journal.pcbi.1005500
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
RESEARCH ARTICLE
Semantic prioritization of novel causative
genomic variants
Imane Boudellioua1, Rozaimi B. Mahamad Razali1, Maxat Kulmanov1, Yasmeen Hashish1,
Vladimir B. Bajic1, Eva Goncalves-Serra2, Nadia Schoenmakers3, Georgios
V. Gkoutos4,5,6*, Paul N. Schofield7*, Robert Hoehndorf1*
1 King Abdullah University of Science and Technology, Computer, Electrical & Mathematical Sciences and
Engineering Division, Computational Bioscience Research Center, Thuwal, Saudi Arabia, 2 Wellcome Trust
Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom, 3 University of Cambridge
Metabolic Research Laboratories, Wellcome Trust—Medical Research Council, Institute of Metabolic
Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, 4 College of Medical and Dental Sciences,
Institute of Cancer and Genomic Sciences, Centre for Computational Biology, University of Birmingham,
Birmingham, United Kingdom, 5 Institute of Translational Medicine, University Hospitals Birmingham, NHS
Foundation Trust, Birmingham, United Kingdom, 6 Institute of Biological, Environmental and Rural Sciences,
Aberystwyth University, Aberystwyth, United Kingdom, 7 Department of Physiology, Development &
Neuroscience, University of Cambridge, Cambridge, United Kingdom
* g.gkoutos@bham.ac.uk (GVG); pns12@hermes.cam.ac.uk (PNS); robert.hoehndorf@kaust.edu.sa (RH)
Abstract
Discriminating the causative disease variant(s) for individuals with inherited or de novo
mutations presents one of the main challenges faced by the clinical genetics community
today. Computational approaches for variant prioritization include machine learning meth-
ods utilizing a large number of features, including molecular information, interaction net-
works, or phenotypes. Here, we demonstrate the PhenomeNET Variant Predictor (PVP)
system that exploits semantic technologies and automated reasoning over genotype-phe-
notype relations to filter and prioritize variants in whole exome and whole genome sequenc-
ing datasets. We demonstrate the performance of PVP in identifying causative variants on a
large number of synthetic whole exome and whole genome sequences, covering a wide
range of diseases and syndromes. In a retrospective study, we further illustrate the applica-
tion of PVP for the interpretation of whole exome sequencing data in patients suffering from
congenital hypothyroidism. We find that PVP accurately identifies causative variants in
whole exome and whole genome sequencing datasets and provides a powerful resource for
the discovery of causal variants.
Author summary
We address the problem of how to distinguish which of the many thousands of DNA
sequence variants carried by an individual with a rare disease is responsible for the disease
phenotypes. This can help clinicians arrive at a diagnosis, but also can be instrumental in
improving our understanding of the pathobiology of the disease. Many methods are cur-
rently available to help with the problem of determining causative variant, using informa-
tion about evolutionary conservation and prediction of the functional consequences of
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the sequence variant. We have developed a novel algorithm (PVP) which augments exist-
ing strategies by using the similarity of the patients phenotype to known phenotype-geno-
type data in human and model organism databases to further rank potential candidate
genes. In a retrospective study, we apply PVP to the interpretation of whole exome
sequencing data in patients suffering from congenital hypothyroidism, and find that PVP
accurately identifies causative variants in whole exome and whole genome sequencing
datasets and provides a powerful resource for the discovery of causal variants.
Introduction
Since the first successful identification of disease-causing variation From whole exome
sequencing in 2010 [1], impressive advances have been made in the field of next generation
sequencing and its related analysis, with the aim of fulfilling the promise of whole exome
(WES) and whole genome (WGS) sequencing for personalized medicine. Such approaches
have revolutionized our ability to identify the genetic underpinnings of disease as well as
improve our capacity to stratify patient populations and diagnose them in a more accurate and
timely manner [2]. A recent critical study provided some objective estimates of the efficiency
of diagnoses by traditional medical genetics diagnostic approaches, with 54% of referred
patients undiagnosed [3]. The introduction of next generation sequencing (NGS) technologies
in clinical settings is anticipated to improve diagnosis efficiency, and between 13% [4] to 50%
of those remaining undiagnosed are likely to receive a molecular diagnosis following WES or
WGS [5]. Nevertheless, the success rate of the state-of-the-art tools for identifying causative
variants using WES data range between 22% to 25% [6, 7], and WGS data in a similar range
[8] depending on the disease type and the availability of sequence data from family members.
The identification of the causative disease mutations in an individual patient remains a
challenge due to the complexity and scale of the task. An individual exome might contain
20,000-30,000 variants with respect to the reference genome; a third of which might comprise
non-synonymous variation [9]. Many thousands of variants in an average genome might be
unique, and on average 20 genes may have complete loss of function (LOF) mutations [10]
whose physiological consequences for the bearer are unpredictable [11]. Adding to the com-
plexity of analysis are contingencies such as oligogenicity and haploid insufficiency. Oligogeni-
city is the phenomenon where additional genes modify the phenotypic effect of a variant in a
primary gene, so that the overall disease phenotype is the consequence of multiple variants in
the same genome. Haploid insufficiency describes a situation where loss of function of one
allele of a gene in a normal diploid cell or individual results in an abnormal phenotype. For
many genes, loss of function of one allele is not significant, but for some genes, dosage is criti-
cal and phenotypic effects are seen with the loss of one allele. Consequently, in haploid insuffi-
ciency, a heterozygote with a loss of function allele may develop an abnormal phenotype [12].
Given these phenomena, it is clear why finding the “needle in a stack of needles” [13] remains
one of the key challenges in fully utilizing WES and WGS data for personalized medicine.
The main approaches taken to prioritize the pathogenic consequences of genomic muta-
tions involve variant calling to identify variants from raw sequencing data, filtering by variant
quality, filtering by minor allele frequency, and then successive assessment of variant proper-
ties based on its potential to affect protein integrity and function, for example, by the insertion
of nonsense codons or indels, compromising the function of active sites, protein-protein inter-
actions, dominant or recessive inheritance, physico-chemical properties, sequence conserva-
tion [14], or analysis of changes in the DNA regulatory domains [15]. Although the majority
Semantic variant prioritization
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of the methods currently used to assess pathogenicity of a variant are focused on exonic varia-
tion, there are also methods that examine non-coding sequences, notably GWAVA, CADD,
DANN, FATHMM-MKL, and others [16–20].
However, many of these methods alone are not able to identify the causative variants under-
lying a patient’s phenotype and require additional investigation, such as analysis of additional
family members, to look for de novo variants, identification of shared rare variants in unrelated
individuals with similar diseases [21], and identity-by-descent inference [2].
Prioritizing disease candidates by using phenotypic similarity to known diseases and char-
acterized non-human disease models can potentially add an additional layer of discrimination
to gene prioritization, but until recently the ability to computationally establish formal pheno-
typic relatedness at scale was not possible. Two crucial developments have enabled the compu-
tational integration and comparison of phenotypes: the systematic application of the PATO
framework [22, 23] and the development of the cross-species anatomy ontology Uberon [24].
While PATO provides a uniform way of describing phenotypes, Uberon can be used to sys-
tematically describe and relate anatomical structures between species. In 2011, PhenomeNET
[25] was developed to exploit phenotype-genotype associations observed in humans and
model organisms and prioritize candidate causal genes based on patient phenotypes. Phenom-
eNET makes use of axioms and formal definitions in the major phenotype ontologies using
the PATO ontology [22] to formally integrate species-specific phenotypes [26–30]. It gathers
phenotype data from model organism and human genotype-phenotype databases, applies
measures of phenotypic similarity and then systematically compares them across species. Phe-
nomeNET has been demonstrated to provide a high degree of predictive accuracy for the dis-
covery of animal models of human disease [31], novel pathways [32], gene function [33], and
druggable therapeutic targets [34]. Since the introduction of PhenomeNET, several further
methods have been been developed that take advantage of this approach and utilize phenotypic
similarity between patients and gene-phenotype associations in public databases to improve
variant prioritization for WES datasets [35–37].
We developed PhenomeNET Variant Predictor (PVP) to prioritize causal variants based on
comparing patient phenotypes with gene-phenotype associations made in humans and model
organisms. PVP combines two main sources of information: molecular and phenotypic. We
use molecular information from multiple pathogenicity prediction tools to identify the patho-
genicity of a variant and the phenotypic information to determine whether a variant is causa-
tive. PVP facilitates a highly accurate identification of causative variants from both WES and
WGS datasets, and we demonstrate the performance of PVP on a set of synthetic and real
whole exome and whole genome sequences. Our results demonstrate that PVP significantly
outperforms other state of the art tools revealing that phenotypic similarity can provide a pow-
erful approach for prioritizing causal variants.
Results and discussion
Integration of genotype and phenotype information predicts causal
variants in whole exome and whole genome sequencing
PVP has been developed to facilitate the identification of causative variants in genomic data
(whole exome or whole genome). We consider a variant to be causative if it is both pathogenic
(evaluated based on molecular information) and involved in developing the patient’s pheno-
type (evaluated based on the gene–disease similarities provided by PhenomeNET). Variants
may be pathogenic but not causative if they are not involved in the pathogenesis of the
patient’s phenotype [11], whilst non-functional, benign variants are generally not causative.
Semantic variant prioritization
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In PVP, we combine methods to determine whether a variant is pathogenic (i.e., functional)
with information about the phenotypes in which a gene is known to be involved to identify
candidate causative variants in WES and WGS data. For predicting pathogenicity, we utilize
tools that can provide a pathogenicity score for every variant within a genome, i.e. CADD [17],
DANN [18], and GWAVA [16]; for the latter, we use an improved version of the Phenom-
eNET framework to match a patient’s phenotypes with a database of gene-phenotype associa-
tions derived from human, mouse and fish resources. The full list of features used for
prediction in PVP is provided as S1 Table. PhenomeNET consists of a repository of gene-phe-
notype associations from human and model organisms, an ontology that integrates pheno-
types across species, and a semantic similarity measure that determines the similarity between
two sets of phenotypes. It provides a score that measures the similarity between a set of patient
phenotypes and sets of phenotypes in the PhenomeNET repository.
Depending on the intended application, the choice of gene-phenotype associations can
strongly affect the performance of PhenomeNET [31]. Here, we utilize two overlapping sets of
gene-phenotype associations; we include gene-phenotype associations observed in zebrafish
and mouse (marked “Model” for Model Organism Databases), and additionally include
human phenotypes propagated from known gene-disease and disease-phenotype associations
(marked “Human” in our experiments). We also use both genotype-phenotype associations
together.
We represent variants by their pathogenicity scores, the scores provided by the Phenom-
eNET system to measure similarity between the patient’s phenotype and known phenotypes
associated with the gene affected by the variant, a small set of high-level phenotypes observed
in a patient, as well as mode of inheritance of the disease (if known) and zygosity of the variant.
We use these as features to train a random forest classifier that separates variants into causative
variants and non-causative variants. Initially, we use 80% of the pathogenic variants available
from the ClinVar database [38] to train our model, keeping 20% of the ClinVar variants for
further testing. In 10-fold cross validation on these 80%, our model achieves an area under the
receiver operating characteristic curve (ROC AUC) of up to 0.994 and F-measure of up to
0.963 (S2 Table).
To test the performance of this model in identifying causal variants in sequencing data, we
generated a synthetic dataset of 11,251 whole genomes sequences (one for each of the 20% var-
iants in ClinVar that were not used to train the model). The synthetic dataset was created by
randomly choosing one of the WGS samples from the 1,000 Genomes Project (1KGP) [39]
and inserting a single causative variant in each of these. 8,746 causative variants were inserted
in exonic regions and 2,505 in non-exonic regions. Next, we mark the synthetic individual as
having the disease and use the phenotypes associated with the disease in the HPO database
[40] as the patient phenotypic profile before trying to recover the inserted pathogenic variant
using our PVP-based models. Before applying our PVP models, we apply a filter to remove
variants with 1% global minor allele frequency from 1KGP on each variant.
We perform two experiments to test the performance of PVP, PVP-Human and PVP-Mo-
del. First, we remove all non-exonic variants from the synthetic genomes to simulate a WES
dataset and employ the resulting WES dataset to assess our recovery rate of causative variants
located in an exonic region. We identify 45.82% of the candidate causative variants as the top
ranked and 72.64% of the causative variants in the top 10 ranked variants for WES data using
only model organism phenotypes to determine phenotypic similarity, 79.21% of variants top-
ranked and 87.94% variants in the top 10 ranks when using only human phenotypes, and
78.80% top-ranked and 89.50% within the top 10 when using both human and model organ-
ism phenotypes together. As second experiment, we apply our approach to all variants in the
whole genome sequences, and recover 12.62% of the variants at first rank and 23.75% within
Semantic variant prioritization
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the first 10 ranks using only model organism phenotypes, 75.10% variants top-ranked and
89.36% in the top 10 ranks using only human phenotypes, and 76.47% top-ranked and 88.61%
within the top 10 when using both model organism and human phenotypes. Tables 1 and 2
summarize these results.
We compare our method against several state of the art variant prioritization tools, namely
CADD [17], DANN [18] and GWAVA [16], as well as the phenotype-based tools Exomiser/
Genomiser [41, 42], Phevor [35] and eXtasy [37]. Our results and the comparison with state of
the art tools is summarized in Tables 1 and 2 as well as Figs 1 and 2, demonstrating that PVP
outperforms the other methods in our experiments.
We further assess how well our method performs on identifying causative variants for dis-
eases with different mode of inheritance (MOI) in WES data. The percentage of cases in which
the causal variant is ranked first is shown in Table 3. We find that, unsurprisingly, our models
perform better on recessive diseases as the variants have to be homozygous, which can be used
as an additional filter, while a dominant mode of inheritance may be caused by either hetero-
zygous or homozygous variants, and complicated by haploid insufficiency, and hence cannot
be used to discriminate between causative and non-causative variants.
To evaluate the importance of the “depth” of phenotyping [43] for predicting candidate var-
iants, we compared the predictive accuracy of PVP with the information content in the disease
(or patient) description. Information content of a phenotype class is measured by its depth in
the PhenomeNET ontology and the number of diseases in our sample that contain this pheno-
type. For diseases associated with multiple phenotypes, we sum the information content of the
individual phenotype classes. We evaluate the correlation between the rank of the causative
variant in our set of 8,746 synthetic exome sequences and the information content associated
with the disease, and find a negative correlation (Spearman’s rank correlation ρ = −0.54), i.e., if
the information content of the phenotypes used to characterize the disease (or patient) is
higher, PVP can provide better predictions.
The set of phenotypes observed in patients is not always complete, or patients may suffer
from multiple co-morbidities that can affect our phenotype-based analysis. To determine the
effect of noise on our analysis, we focus on a subset of 8,522 out of 8,746 synthetic whole
exome sequences for which the disease is characterized phenotypically (the remaining cases
were imputed by our algorithm, see Materials and Methods), and we perform two experiments
(see S3 Table): first, we randomly add the phenotypes of a second disease to the phenotypes of
the patient to simulate co-morbidity; and second, we randomly remove each phenotype used
Table 1. Overview of how many causative variants out of 8,746 exonic were recovered on rank 1 and within the top 10 ranks by PVP and PVP-Hu-
man, and comparison to CADD, DANN, GWAVA, Exomiser eXtasy, and Phevor. Analysis was performed on WES data. If a tool did not provide a score
for a causative variant, we excluded the variant from this table; consequently, the total number of samples analyzed differs between the methods and the per-
centages reported are based on the number of samples for which the causative variant was ranked.
Top hit (exonic) Top 10 (exonic) Total (exonic) Median (exonic)
CADD 1,095 (15.15%) 2,317 (32.05%) 7,229 49
DANN 406 (6.06%) 1,789 (26.69%) 6,704 108
GWAVA 102 (1.41%) 458 (6.32%) 7244 339
eXtasy 553 (14.85%) 1,601 (42.99%) 3,724 19
Exomiser 2,156 (24.65%) 5,122 (58.56%) 8,746 5
Phevor 1,679 (28.25%) 3,845 (64.70%) 5,943 4
PVP-Model 4,007 (45.82%) 6,353 (72.64%) 8,746 2
PVP-Human 6,928 (79.21%) 7,691 (87.94%) 8,746 1
PVP 6,892 (78.80%) 7,828 (89.50%) 8,746 1
https://doi.org/10.1371/journal.pcbi.1005500.t001
Semantic variant prioritization
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to characterize the patient’s disease with a probability of 1/3 (i.e., on average, 1/3 of the pheno-
type annotations for each disease are removed). Using the PVP-Human model, we find that in
the first experiment, only 3,547 (41.62%) variants are ranked first and 4,315 (50.63%) in the
top 10, compared to over 75% ranked first with phenotypes matching the disease exactly. In
our second experiment, removing phenotypes with probability 1/3 results in 3,963 (46.50%) of
causative variants ranked first and 4,921 (57.74%) in the top 10. We further investigated how
well PVP can distinguish between variants that are causative for closely related diseases. For
this purpose, we insert a second causative variant v2 to the whole exome sequence of the syn-
thetic patients (each containing a single causative variant v1). The second variant v2 is chosen
Table 2. Overview of the performance of PVP, CADD, DANN, GWAVA and Exomiser in prioritizing causative variants in WGS data. We prioritize all
variants in a VCF file resulting from WGS using the same models. Analysis is separated reflecting the performance of the various tools identifying exonic and
non-exonic variants. For CADD, DANN, and GWAVA, we report only analysis results for which a prediction score is returned; consequently, total numbers are
less than the total of 11,251 causative variants.
PVP
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 6,500 74.32% 7,595 86.84% 8,746
Non-exonic 2,104 83.99% 2,374 94.77% 2,505
Total 8,604 76.47% 9,969 88.61% 11,251
PVP-Model
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 1,012 11.57% 1,992 22.78% 8,746
Non-exonic 435 17.37% 703 28.06% 2,505
Total 1,447 12.86% 2,695 23.95% 11,251
PVP-Human
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 6,611 75.59% 7,620 87.13% 8,746
Non-exonic 2,156 86.07% 2,368 94.53% 2,505
Total 8,767 77.92% 9,988 88.77% 11,251
CADD
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 441 6.1% 1759 24.33% 7229
Non-exonic 118 4.77% 599 24.2% 2475
Total 559 5.76% 2358 24.3% 9704
DANN
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 325 4.85% 1287 19.2% 6704
Non-exonic 101 5.32% 347 18.27% 1899
Total 426 4.95% 1634 18.99% 8603
GWAVA
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 34 0.47% 44 0.61% 7244
Non-exonic 9 0.42% 22 1.04% 2121
Total 43 0.46% 66 0.7% 9365
Exomiser/Genomiser
# top 1 hits % top 1 hits # top 10 hits % top 10 hits Total
Exonic 2,747 31.41% 6,879 78.65% 8,746
Non-exonic 780 31.14% 1,895 75.65% 2,505
Total 3,527 31.35% 8,774 77.98% 11,251
https://doi.org/10.1371/journal.pcbi.1005500.t002
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to be causative for the most phenotypically similar disease (within our test dataset). We then
use the phenotypes associated with v1 and test at which rank v1 and v2 are predicted by PVP.
Using PVP-Human, we find v1 ranked first in 62.38% of the cases, while v2 is ranked first in
15.36% of the cases, demonstrating that PVP can also discriminate between closely related dis-
eases. Combining the phenotypes associated with v1 and v2, we predict both v1 and v2 with
equal probability of 37% on the first rank (see S3 Table).
To make PVP available as a tool for diagnostic support, we re-train all our models using the
whole ClinVar dataset and combine the phenotype similarity computation using Phenom-
eNET with annotation of pathogenicity into the PVP tool. PVP can analyze WES or WGS
Fig 1. Performance of PVP in retrieving causative variants in whole exome sequences. Results are compared against CADD, DANN, and GWAVA,
and the phenotype-based tools Exomiser, Phevor and eXtasy.
https://doi.org/10.1371/journal.pcbi.1005500.g001
Fig 2. Performance of PVP in identifying causative variants in whole genome sequences using human phenotypes (PVP-Human), model
organisms phenotypes (PVP-Model), and combined phenotypes (PVP), and comparison of PVP to CADD, DANN, GWAVA, and Genomiser.
https://doi.org/10.1371/journal.pcbi.1005500.g002
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datasets using the VCF file and a set of observed patient phenotypes as input and then output-
ting a list of variants ranked by the likelihood they are causative for the observed phenotypes.
PVP predicts causative variants in diagnosed cases
We evaluate the performance of PVP on a series of real exomes from individuals diagnosed
as having Congenital Hypothyroidism (CH), included in the UK10K dataset [44] (see Meth-
ods), to assess how well we could recover potentially pathological variants in genes already
associated with the disease. Congenital hypothyroidism is one of the most frequent endo-
crine disorders of the neonate with a frequency of up to 1/1,500 births [45], although some
forms and molecular etiologies can be much more rare, such as Central Congenital Hypo-
thyroidism (CCH) [46] estimated at around 1/16,000. Historically, most cases were thought
to be due to thyroid gland dysgenesis comprising ectopias, hypoplasia and complete agenesis
[47]. However, recently, an increase in diagnosis of CH in the presence of apparently
anatomically normal glands (gland-in-situ) has been reported [45]. The pathophysiology of
such cases may include organisational and functional defects (dyshormonogenesis) within
the glands leading to compromised or absent function. A range of genes has been implicated
in these processes which include thyroid transcription factors, genes involved in thyroid
hormone biosynthesis, and the Thyroid Stimulating Hormone receptor (TSHR) [48]. Muta-
tions in known genes are implicated in less than 5% of thyroid dysgenesis cases, whereas
dyshormonogenesis is usually associated with mutations in components of the thyroid hor-
mone biosynthetic machinery [47].
We analyze 43 individuals from the UK10K rare disease cohort of patients and relatives
with congenital hypothyroidism, using PVP. The dataset includes 11 confirmed cases of thy-
roid dysgenesis (DG), 30 CH with gland-in-situ (GIS, likely involving dyshormonogenesis),
and two with CCH, in addition to 80 individuals that do not show any phenotypes but have a
family relation to the affected individuals. We use a common set of phenotypes from the HPO
for the whole cohort, comprising hypothyroidism (HP:0000821), congenital hypothyroid-
ism (HP:0000851), TSH excess (HP:0002925), thyroid hypoplasia (HP:0005990), and
TSHR defect (HP:0011791); these are the most relevant phenotypes in HPO. We analyze the
individual cases independently and do not account for the relationships between individuals.
Thirty six of these show variants in genes already associated with CH within the top 20 hits, fil-
tered for a minor allele frequency (MAF) of 1% (S4 Table) while the remainder do not show
known CH-associated disease genes above this rank. We do not, in the current study, further
analyze the likelihood that high ranking genes in these 7 individuals might represent novel
genes in this disease or differential diagnoses.
Of the 11 cases of thyroid dysgenesis, 9 show homozygous or heterozygous alleles of genes
already implicated in dysgenesis-associated CH within the first five ranked hits. All were
assessed as deleterious or possibly deleterious by SIFT [49], PolyPhen [50], or both. These
genes include GLIS3 [51], NKX2-1 [52], and PAX8 [53]. One case shows a predicted deleterious
allele of LHX3 normally associated with CCH through an effect on pituitary development [46].
Table 3. Performance of PVP in variant prioritization in WGS data, separated by mode of inheritance of the disease.
Coding Noncoding
Dominant Recessive Others/Unknown Dominant Recessive Others/Unknown
PVP 4006 (77.61%) 2005 (93.26%) 881 (61.44%) 1178 (83.66%) 684 (97.3%) 310 (78.68%)
PVP-Model 2100 (40.68%) 1535 (71.40%) 372 (25.94%) 754 (53.55%) 587 (83.50%) 179 (45.43%)
PVP-Human 4027 (78.01%) 1993 (92.7%) 908 (63.32%) 1197 (85.01%) 686 (97.58%) 321 (81.47%)
https://doi.org/10.1371/journal.pcbi.1005500.t003
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Of the cases with GIS all but 9 show deleterious alleles in DUOX2 [54], TG [55], or TPO
[56], and in some cases predicted pathogenic variants of two or three of these genes are found
together in the highest ranks in our analysis. The remainder show variants in NKX2-1, LHX3,
and, in one case, PAX8. Homozygous alleles in DUOX2 and TPO are present in 15 individuals.
One homozygous variant has been previously reported in ClinVar to be pathogenic and affects
iodotyrosyl coupling (NM_003235.4(TG):c.638+5G>A) [57]. In five cases of GIS, homozy-
gous mutations of TG are found in the same individual as deleterious heterozygous DUOX2
alleles. In one case, a homozygous DUOX2 allele is found with a compound heterozygote in
TG.
While our analysis of the complete dataset provides hypotheses about the most likely dis-
ease-causing variants, confirmation requires detailed analysis and re-sequencing. Of the 43
cases we analyze, 15 individuals with CH were previously subjected to Sanger sequencing of
candidate variants, confirming the association with the disease [58]. In 9 of these 15 cases,
PVP correctly implicates the likely causative alleles as the first hit. In six of the cases, potentially
deleterious mutations are found in two genes, and in five of these six cases, PVP correctly iden-
tifies the second gene within the first 10 ranks. Additionally, multiple mutations in TG are
found in three cases, and in two of these, PVP identifies the second variant as the second rank
(S5 Table). The unexpected involvement of oligogenic and triallelic loss of function/hypo-
morphic mutations in the genesis of congenital thyroid disease is discussed in [58].
We also test PVP with diseases displaying different sets of phenotypes. We utilize data avail-
able from the Personal Genomes Project (PGP) [59] and examine if we can predict disease-
associated variants consistent with the information that patients that participate in the PGP
have declared. We analyze two patients from the PGP, one patient (PGP:hu92FD55) with a
disease in mental functioning (Asperger’s Syndrome) the other (PGP:hu432EB5) with
hemostasis abnormalities (Von Willebrand disease). For the individual associated with Asper-
ger Syndrome (OMIM:300494), the top variant predicted by our approach is in PLCB1, phos-
pholipase C beta 1, located at 20p12.3. PLCB1, which is involved in extracellular signal
transduction in the phosphoinositol pathway, has been implicated in GWAS analysis for
autism spectrum associated phenotypes in the ALSPAC study [60] and a homozygous deletion
in a single case of malignant migrating partial seizures in infancy (MMPEI) [61]. Rare muta-
tions associated with autistic spectrum disorders, largely small deletions and duplications,
have been reported within and around the gene [62]. The variant seen here is predicted to be
pathogenic, heterozygous, and has not been previously reported, suggesting that this is not a
simple LOF mutation as seen in MMPEI, and may warrant further research. For the case of the
patient associated with von Willebrand disease (OMIM:193400) [63], VWF is the top hit in
our analysis, identifying the variant (chr12:6143978G>A), already described as pathogenic.
This individual is heterozygous, consistent with the known pathogenesis of type 1 von Willeb-
rand disease.
Effects of datasets and evaluation method
PVP provides a system for prioritization of causative genomic variants. While other systems
have previously used phenotypes for variant prioritization [35, 37, 41, 42], key novelties of
PVP are a novel cross-species phenotype ontology and the way in which gene-phenotype
information is used for variant prioritization. The choice of gene-phenotype associations
strongly determines the performance of the system and possible application scenarios. In par-
ticular, in contrast to systems such as Phevor or Exomiser, we explicitly provide PVP with the
option to ignore human phenotype information and rely only on independent data from
model organisms. Human phenotypes, provided by the HPO project [40], are derived from
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disease phenotypes by identifying causative genes for a disease and propagating the pheno-
types associated with the disease to the known disease genes. While we observe a strong
increase in performance when using these propagated human phenotypes, methods that are
trained using them will likely over-emphasize known disease genes and therefore only provide
limited performance in identifying variants in novel disease genes.
Another observation from our experiments is that the type of evaluation has a strong
impact on the reported performance. We evaluate PVP and related variant prioritization sys-
tems using ClinVar variants, and, since PVP was trained using this dataset, we specifically eval-
uate PVP and the other systems using a 20% holdout set that we have not used for training our
models so that we can determine its performance on unseen variants. While we find that PVP
performs comparably to, or better than, other systems in our experiments using WES data, we
also observe a striking difference in performance to previously reported results for some vari-
ant prioritization systems. For example, Exomiser has been reported to identify up to 97% of
causative variants on the first rank in prior experiments using WES data [41], and over 70% of
causative variants on the first rank in WGS data [42]. The main difference between our experi-
ments and those performed to evaluate Exomiser/Genomiser is the use of a different evalua-
tion dataset which only partially overlaps with the dataset used to evaluate Exomiser/
Genomiser. Additionally, the results reported in the evaluations of Exomiser and Genomiser
[41, 42] that found up to 97% of variants to be predicted correctly were performed on the mod-
el’s training data, i.e., using an overfitted model [41]. Such a strategy will be able to accurately
find known variants (i.e., variants on which the model has been trained), but, as demonstrated
by our results, will perform with lower accuracy on previously unseen or novel data.
In PVP, we chose to focus on two different application scenarios that should be among the
most useful in the task of interpretation of variants in a clinical setting: identification of causa-
tive variants in known disease genes (using PVP-Human), and identification of causative vari-
ants in potentially novel genes (using PVP-Model or PVP).
Impact of the use of model organism phenotypes on variant prioritization
and disease gene discovery
Use of phenotypic similarity of experimental mouse models to human diseases has been
shown to guide the discovery of the associated human gene. For example the mouse “hairless”
mutation was first described in 1859 and the gene identified in 1994 [64]. On the basis of phe-
notypic similarity to alopecia universalis, the human gene was identified as the human homo-
logue of mouse “hairless” in 1998 [64]. In PVP, phenotype data from mouse and fish models is
particularly useful when no human phenotypes are available for a gene, i.e., when a variant is
in a gene not previously implicated in a disease. Currently (23 Jan 2017), mouse phenotypes
are available for 9,045 mouse genes with human orthologs, but only 3,698 genes are associated
with phenotypes in OMIM, and we evaluated the effect of using mouse phenotype data for var-
iants in genes without available human phenotypes (see S6 Table).
In our analysis, we can identify a variant (rs766783183) in the keratin 25 (KRT25) gene
at rank 8 for Hypotrichosis 8 (OMIM:278150) in our analysis based on a strong concordance
between mouse phenotypes (all of which are associated with hair and nail morphology and
hair growth) and the phenotypes associated with the human disease. Using PVP without
model organism phenotypes results in rank 172 for the same variant. Similarly, we can
improve the rank of a variant (rs764239923) in the Gliomedin (GLDN) gene as causative
for lethal congenital contracture arthrogryposis-11 (OMIM:617194) from rank 342 without
model organism phenotype to rank 7 using model organism phenotypes based on matching
nervous system abnormality phenotypes in the mouse.
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However, in some cases, the model organism phenotypes add noise to the results, especially
where there are discordant phenotypes, either for reasons intrinsic to the disease, due to differ-
ences in human and mouse physiology, or because the scope of phenotyping in the model
organism is distinct from that carried out on humans. For example, a variant
(rs121908425) in the collapsin response mediator protein 1 (CRMP1) gene would be priori-
tized at rank 1 for the disease Ellis-van Creveld syndrome (OMIM:225500) without relying
on any phenotypes and based on pathogenicity of the variant alone. All phenotypes associated
with the mouse ortholog Crmp1 are associated with abnormal nervous system physiology and
morphology, while the phenotypes associated with the human disease relate to a wide range of
morphological abnormalities. Consequently, when relying on PVP-Mod that uses phenotypic
similarity to model organism phenotypes, prediction of the causative variant drops to rank 65.
In our quantitative evaluation, predictive performance including mouse phenotypes is slightly
less than performance relying on human phenotypes alone, demonstrating (unsurprisingly)
that model organism phenotypes are overall less similar to a human disease than phenotypes
observed in humans. However, in particular in cases where no human phenotypes are available
or causative variants occur in genes not previously implicated in a disease, model organism
phenotypes may aid in identifying causative variants. In the future, methods should be devel-
oped that can determine automatically whether the phenotypes observed in a model organism
are of sufficient quality and depth to contribute to prioritization of causative variants.
Conclusions
Mobilizing the volume and richness of genotype-phenotype associations From human and
model organism databases provides a powerful resource with which potential disease candi-
dates can be discriminated. Data From large scale mutagenesis efforts and hypothesis-driven
science have created sufficient genotype-phenotype association data. PhenomeNET [25] was
developed as a framework that exploits these phenotypes in a computational approach, using
phenotypes as surrogates for their underlying genes. By identifying relations between pheno-
types, PhenomeNET identifies the similarity between the underlying molecular processes and
their components. We have developed PVP as a computational method to prioritize variants,
and we demonstrate here using synthetic and real patients’ genomic data that PVP is a system
for highly accurate genome-scale identification of causative variants involved in human dis-
ease. PVP on its own relies only on model organism phenotypes and is particularly useful
when variants in potentially novel genes should be found; PVP-Human emphasizes variants in
known disease genes and should be used when variants are suspected in genes already known
to be involved in the pathogenesis of a disease.
Materials and methods
Updates to the PhenomeNET system
Changes in the HPO, MP and other ontologies, as well as improved OWL reasoning technolo-
gies [65], allowed us to improve upon the method originally used to build the PhenomeNET
[25] to generate a more comprehensive phenotype ontology spanning zebrafish, mouse and
human. PhenomeNET includes all classes contained in the HPO, MP, but is formalized pri-
marily based on the structure of anatomy and physiology ontologies [66]. All our experiments
are based on ontology versions downloaded from the AberOWL ontology repository [67] on
10 June 2016, and all ontologies included in the PhenomeNET ontology are from this date.
The PhenomeNET ontology includes UBERON [24], GO [68], BSPO [69], ZFA [70],
PATO [22], CL [71], NBO [72], but removes all disjointness axioms from these ontologies
prior to inclusion due to possible inconsistencies arising from these. Furthermore, the
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PhenomeNET ontology includes the CHEBI [73] and MPATH [74] ontologies as imports.
Within the PhenomeNET ontology, axioms are rewritten to follow the phene pattern [66] so
that phenotypes are primarily organized by anatomical structure or physiological process.
In particular, within HPO and MP, we identify axioms for a phenotype class P by identify-
ing a class E and Q, and reformulate the formal definition of P as P EquivalentTo:has-
part some (E and has-qualitysome Q). We initialize E and Q with owl:Thing and
then generate axioms from the definition of P provided by HPO or MP using the following
rules:
• modifiersome X: we keep the object property and target class as modifier of the quality
Q, setting Q≔ Q and modifiersome X
• inheres-insome X: set E≔ X
• inheres-in-part-ofsome X: set E≔ part-ofsome X
• towardssome X: set E≔ E and towardssome X
• has-qualitysome X: set E≔ E and has-qualitysome X
• exists-duringsome X: set E≔ E and exists-duringsome X
• has-partsome X1 and . . . and has-partsome Xn: treated as intersection, P≔ X1
and . . . and Xn
• part-ofsome X: set E≔ E and part-ofsome X
• has-central-participantsome X: set E≔ E and has-central-partici-
pant some X
• results-fromsome X: set E≔ E and results-fromsome X
• occurs-insome X: set E≔ E and occurs-insome X
These axioms are intended to reformulate axioms in the HPO and MP so that each pheno-
type class characterizes a whole organism that has an entity E as part which is further charac-
terized by its qualities and relations to other entities. Furthermore, the axioms aim to enforce a
taxonomic structure that closely resembles anatomy (from Uberon) and physiology (from
GO). Specifically, if X is a subclass of part-ofsome Y in either Uberon or GO, the axioms
aim to force X phenotype to become a subclass of Y phenotype. To completely resemble
parthood relations, we further generate an additional phenotype class S for each unique E that
we identify, using the axiom S EquivalentTo:has-partsome (part-ofsome (E
and has-qualitysome owl:Thing)). This class serves as additional class that is not
usually present in either HPO or MP, and enforces the taxonomic structure of the Phenom-
eNET ontology to follow both the taxonomic structure and parthood structure of the GO and
Uberon.
Zebrafish phenotypes are not represented using a dedicated phenotype ontology but rather
annotated using E and Q classes directly. Within the PhenomeNET ontology, we generate one
class for each unique combination of E and Q found in annotations to zebrafish models. If two
entities are used to annotate a zebrafish model (i.e., E1 and E2, we generate the axiom P≔
has-partsome (E1 and has-qualitysome (Q and towardssome E2)).
The ontology structure is not manually created but must be inferred using deductive rea-
soning. We rely on the ELK reasoner [65] to infer the ontology structure. The PhenomeNET
ontology is updated regularly, is freely available and can be queried using the ELK reasoning
in the AberOWL ontology repository [67].
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Model organism phenotypes and similarity search
We collected the mutant model organism phenotypes for mouse from the MGI database [75]
on 14 December 2015, human phenotypes From the HPO database [40] on 14 December
2015, and zebrafish phenotypes from the ZFIN database [70] on 13 December 2015.
We compute semantic similarity between a patient phenotype and the collection of model
organism and human phenotypes using Resnik’s measure [76] with the Best Matching Average
(BMA) strategy for combining pairwise similarities. We use Resnik’s information content
measure [76] computed over the corpus of gene-phenotype associations (from human, mouse
and zebrafish) as specificity measure for each class in the phenotype ontology. Semantic simi-
larity is computed using the Semantic Measures Library [77]. We normalize semantic similar-
ity values to the range of [0, 1] for the annotation of variants by dividing each similarity value
by the maximum similarity observed for each patient phenotype profile.
Generation of model training data
To train our models, we used the set of variants from ClinVar [38]. ClinVar is a public archive
of human variations with their corresponding clinical significance. Clinical significance infor-
mation in ClinVar is provided based on the American College of Medical Genetics and Geno-
mics (ACMG) guidance in describing variants identified in genes that cause Mendelian
disorders.
We used ClinVar (dated 05 January 2016) using the reference genome of GRCh37.p13 as
our main set. Within the 120,509 records in this dataset, we identified two sets of variants that
we use for training, a set of pathogenic variants (ClinVar significance code 5) and a set of
benign variants (ClinVar significance code 2). Additionally, for each pathogenic variant, we
obtain the disease that the variant causes, identified through its OMIM identifier [78].
By default, ClinVar grouped a variant with multiple alleles into a single record. By using the
VCF2TSV parser script from VCFLIB (https://github.com/vcflib) we converted the VCF for-
mat file of ClinVar to a tab-delimited format file and split the variants with multiple alleles
into multiple records. We further split variants that are associated with multiple diseases into
multiple records.
Next, we downloaded the mode of inheritance (MOI) for diseases in OMIM From the HPO
phenotype database. We obtained a total of 5,864 MOI records which were classified as “Dom-
inant”, “Recessive”, “Multifactorial”, “Others”, “Sporadic”, “X-linked” and “Y-linked”. We
combined this information with the variants from ClinVar to generate candidate disease-caus-
ing genotypes; if the MOI of the disease associated with a ClinVar variant is “Recessive”, we
generate a single homozygote genotype using the variant; in all other cases, we generate a het-
erozygote as well as a homozygote genotype based on the variant. The results are 43,236 geno-
types classified as pathogenic and 52,084 genotypes classified as benign. This set includes
12,783 pathogenic non-coding variants (i.e., variants that do not lie in an exonic region,
including intronic and intergenic variants).
Generation of synthetic exomes/genomes
So that we can quantitatively evaluate our method, we generated 11,251 synthetic whole
genome sequences corresponding to our hold-out test sets. To generate this test set, we
inserted a single pathogenic variant into a randomly selected whole genome sequence from the
1000 Genomes Project, hg19. In 8,746 of these sequences we inserted an exonic causative vari-
ant and in 2,505 we inserted a non-exonic causative variants. 46 exonic and 7 non-exonic vari-
ants from our holdout set were excluded as they have a MAF higher than our cutoff of 1%. We
generated synthetic exome sequences by removing non-exonic variants from the 8,746 WGS
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files that include an exonic variant. We use these synthetic whole exome and whole genome
sequences to test the performance of our method.
Model training
We split the set of 43,236 pathogenic variants randomly into 80% for training and 20% for test-
ing. We annotated all variants in these sets with methods that can predict pathogenicity of
both coding and non-coding variants. We used the Combined Annotation Dependent Deple-
tion (CADD) [17], Genome Wide Annotation of VAriants (GWAVA) [16] and a deep neural
network approach (DANN) [18] to obtain three pathogenicity prediction scores for each of the
variants. Additionally, we used the genotype (homozygote or heterozygote) of a variant as
feature.
For each variant, we also added features related to the disease the variant is involved in
according to ClinVar. In particular, we added as features the mode of inheritance of the dis-
ease, using only “Dominant”, “Recessive”, “X-linked”, and “Other” as features, and a binary
vector of 54 high-level phenotypes of the disease based on our PhenomeNET ontology com-
bining HPO and MP. Finally, we added the normalized semantic similarity between the disease
phenotypes and the gene in which the variant is located as a feature. If a variant is non-exonic,
we used the gene that is closest to the variant in genomic coordinates as the gene for which
similarity was computed. In total, each variant is represented as 60 features (see S1 Table).
Based on these 60 features, we trained a random forest classifier to classify variants into
causative and non-causative (given a set of phenotypes observed in a patient). We understand
a causative variant as a variant that is both pathogenic and involved in the pathogenesis of the
disease phenotypes observed in the patient. For training, we represented the patient’s disease
phenotypes by the phenotypes associated with the disease in the HPO database. A variant may
be pathogenic but not causative for a set of patient phenotypes [11]. We simulated this case by
randomly selecting another disease from the OMIM database and assigning these phenotypes
as patient phenotypes in the feature representation of the variant. We called these variants
pathogenic non-causative variants. We treated all variants identified as benign in ClinVar as
non-causative and selected the phenotypes of a random OMIM disease to represent them. For
training, missing values were imputed using the C4.5 method [79].
We use pathogenic causative variants as positives, but have two different types of negatives:
pathogenic non-causative variants and benign non-causative variants. We train three models
that emphasize the negative variants differently: a first model uses only pathogenic non-causa-
tive variants as negatives, a second model uses only benign variants as negatives, and a third
model uses 50% pathogenic non-causative and 50% benign non-causative variants as negatives.
Since the first model cannot distinguish variants by their pathogenicity prediction scores
(since both positive and negative variants are pathogenic and only differ in the disease for
which they are causative), it is trained to under-emphasize pathogenicity of a variant and rely
primarily on the phenotype similarity. The second model can clearly distinguish pathogenic
variants from non-pathogenic based on pathogenicity prediction scores and will not have to
rely heavily on the phenotype similarity scores; therefore, it is trained to under-emphasize phe-
notype similarity and predict primarily based on pathogenicity of a variant. The third model
aims to achieve a balance between both.
For each model, we train a random forest binary classifier (using the pre-selected 80% of
the variants in ClinVar [38] while keeping 20% of the variants as holdout set for final valida-
tion) and evaluate the results using stratified 10-fold cross-validation. We trained the models
using the Random Forest implementation in Weka [80] using 100 trees, unlimited depth of
trees, and constructing each tree considering 6 random features. Random forests are trained to
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output probability estimates of class assignment, which we use as prediction score to rank vari-
ants. We report cross-validation evaluation results in S2 Table.
Model evaluation
The trained models are then applied to our synthetic exomes and genomes. Each synthetic
whole exome or whole genome sequence is taken randomly from one of the 1,000 Genomes
project sequences, with one causal variant from our holdout set artificially inserted. We use
the phenotypes associated with the disease for which this variant is causal as patient pheno-
types and use our models to compute a prediction score for each variant in the synthetic
sequences. We then evaluate the ranks on which we recover the causal variant and compare
the results against Exomiser version 7.2.1, Phevor version 2, eXtasy version 0.1beta (for whole
exome sequences only), and CADD version 1.3, DANN version 1, GWAVA version 1, and
Genomiser version 7.2.1 (for whole genome sequences). For evaluation, none of our models
were trained on the variants we inserted in these sequences. We report the area under the
receiver operating characteristic curve (ROC AUC) and the top ranks and top 10 ranks
obtained by applying each method.
We analyze the synthetic whole exome sequences with the Exomiser [41] using the same
sets of phenotypes and mode of inheritance as input and using its variant prioritization mode.
For comparison with Phevor, we first rank variants based on their CADD score and submit
the ranked list to the Phevor web interface using the same phenotypes used in our analysis.
Phevor provides a ranked list of genes, not variants, and we assign variants the Phevor rank of
the gene in which it is located. We performed the analysis with eXtasy using its default parame-
ter settings with imputation of missing values, and combining multiple phenotypes. eXtasy
was not able to utilize all HPO phenotype classes in our analysis and we omitted the pheno-
types that were not available to eXtasy.
In all tools besides PVP, we remove variants for which no rank is assigned from the analysis.
For DANN and GWAVA, this includes all insertions and deletions as they are not scored by
these tools.
PVP
In PVP, we remove all variants that are not clearly identified as homozygote or heterozygote
(e.g., genotypes that were not confidently called). Moreover, if the mode of inheritance of the
disease is known to be recessive, we filter out variants associated with 0/1 genotype call as the
disease will require a variant with a 1/1 genotype call in order to be present. MAF is also used
as a filtering option for some of the experiments we conducted. MAF data were obtained from
the 1000 Genomes Project corresponding to all populations (release August 2015) using the
Annovar tool [81]. The source code of PVP is freely available at https://github.com/bio-
ontology-research-group/phenomenet-vp.
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Data to UK10K samples is available from the European Genome-Phenome Archive through
the UK10K Data Access Committee (datasharing@sanger.ac.uk, https://www.uk10k.org/data_
access.html) for researchers who meet the criteria for access to confidential data.
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